Vera Therapeutics (NASDAQ:VERA) Shares Gap Up – Here’s What Happened

Vera Therapeutics, Inc. (NASDAQ:VERA)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $34.05, but opened at $37.14. Vera Therapeutics shares last traded at $33.16, with a volume of 3,506,658 shares changing hands.

More Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Strong ORIGIN 3 efficacy results: In the final 104-week analysis of 428 patients with IgA nephropathy, TRUTAKNA stabilized kidney function, with an annualized eGFR decline of 0.6 mL/min/1.73m² versus 5.6 for placebo. The treatment also reduced the risk of a composite kidney disease progression event by 76%, with a hazard ratio of 0.24. ORIGIN 3: Atacicept Reduces Kidney Function Decline in IgAN
• Positive Sentiment: Regulatory pathway strengthened: Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full FDA approval, potentially expanding TRUTAKNA beyond its current accelerated approval based on proteinuria reduction. Vera’s TRUTAKNA Shows Two-Year Kidney Protection
• Positive Sentiment: Commercial launch momentum: Vera reported more than 350 patient start forms during TRUTAKNA’s first 10 weeks, along with paid claims and encouraging early payer policies. Safety was generally comparable to placebo, supporting the product’s potential market adoption. Vera’s Trutakna Shows Two-Year Kidney Protection
• Neutral Sentiment: Competitive implications: The data intensify competition in the IgA nephropathy market and could improve Vera’s positioning, but investors may await detailed conference results and additional evidence supporting long-term disease modification. Vera’s Strong Phase 3 IgAN Data Intensify Rivalry
• Negative Sentiment: Profit-taking and remaining risks: Shares initially rallied on the trial win but later reversed and decreased amid heightened volatility. TRUTAKNA remains under accelerated approval, so continued approval depends on confirmation of clinical benefit. Immunosuppression, infections and injection-site reactions, as well as uncertainty over payer uptake and full FDA approval, remain risks.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday. Bank of America raised their price target on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $80.15.

Vera Therapeutics Price Performance

The firm has a market cap of $2.29 billion, a PE ratio of -5.42 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The business’s fifty day moving average is $34.59 and its 200-day moving average is $36.96.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the previous year, the firm earned ($1.20) earnings per share. On average, research analysts predict that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,307,800 over the last three months. 15.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP increased its holdings in Vera Therapeutics by 1,579.2% in the 2nd quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock worth $4,640,000 after acquiring an additional 101,699 shares during the last quarter. Squarepoint Ops LLC boosted its position in Vera Therapeutics by 569.1% during the second quarter. Squarepoint Ops LLC now owns 104,937 shares of the company’s stock worth $4,503,000 after purchasing an additional 89,253 shares during the period. Arizona State Retirement System boosted its position in Vera Therapeutics by 12.3% during the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock worth $507,000 after purchasing an additional 1,295 shares during the period. Nykredit A S purchased a new position in shares of Vera Therapeutics in the second quarter worth about $97,000. Finally, Readystate Asset Management LP bought a new stake in shares of Vera Therapeutics in the second quarter valued at approximately $12,663,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.